Company: Lysosomal Therapeutics
Job title: CSO
Peter Lansbury is Chief Scientific Officer of Lysosomal Therapeutics, Inc. He graduated from Princeton University and received his PhD from Harvard University. After a postdoctoral fellowship at the Rockefeller University, he joined the faculty of the Department of Chemistry at MIT. He moved to the Harvard Medical School in 1996 and was promoted to Professor of Neurology in 2004. He was the founding director of the Morris K. Udall NIH Parkinson’s Disease Research Center of Excellence. He founded Link Medicine and served as its Chief Scientific Officer from 2005 until its sale to AstraZeneca in 2012. He is currently on leave from his position as professsor of Neurology and Harvard Medical School. Peter was a National Science Foundation Presidential Young Investigator and a Zenith Fellow of the Alzheimer’s Disease Association.
Translating Exciting Science into Clinical Success in Parkinson’s Disease; Examples of Synuclein & Glucocerebrosidase Targeting 12:30 pm
• Biomarkers for drug action in the brain are considered to be necessary for big pharma – are they really? • Addressing how selection of patients for early trials is the most important issue • Discussing why the connection between synuclein and Parkinson’s disease is not as clear as you have been led to believeRead more
day: Day Two